Abiraterone acetate (AA) with or without cabazitaxel (CBZ) in treatment of chemotherapy naive metastatic castration-resistant prostate cancer (mCRPC)

被引：0
|
作者：
Slovin, Susan F.
Knudsen, Karen E.
Halabi, Susan
Fleming, Mark T.
Molina, Ana M.
Wolf, Steven Paul
de Leeuw, Renee
Fernandez, Celina
Kang, Praneet
Southwell, Traci
Jones, Carol L.
Fernandez, Escarleth
Kelly, William Kevin
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA USA
[3] Duke Univ, Med Ctr, Durham, NC USA
[4] US Oncol Res, Virginia Oncol Associates, Norfolk, VA USA
[5] Weill Cornell Med, New York, NY USA
[6] Duke Univ, Sch Med, Durham, NC USA
[7] Univ Illinois, Coll Med, Dept Pathol, Chicago, IL 60612 USA
[8] Thomas Jefferson Univ, Philadelphia, PA 19107 USA
[9] Virginia Oncol Associates, Norfolk, VA USA
[10] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
84
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Sequencing of cabazitaxel and abiraterone acetate following docetaxel in metastatic castration-resistant prostate cancer (mCRPC)
    Schnadig, Ian D.
    Bhor, Menaka
    Vogelzang, Nicholas J.
    Hennessy, Daniel
    Nicacio, Leonardo V.
    Berry, William R.
    Hutson, Thomas E.
    Fleming, Mark T.
    Cowey, C. Lance
    Saravanan, Shanmugapriya
    Dhanda, Rahul
    Sonpavde, Guru
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [2] Real-world treatment with abiraterone acetate in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC)
    Boegemann, Martin
    Hatzinger, Martin
    Hercher, Dirko
    Matus, Geoffrey
    Everaert, Els Grieta
    Dopchie, Catherine
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [3] Outcomes with different sequences of cabazitaxel and abiraterone acetate following dooetaxel in metastatic castration-resistant prostate cancer (mCRPC)
    Sonpavde, G.
    Bhor, M.
    Hennessy, D.
    Bhowmik, D.
    Shen, L.
    Nicacio, L.
    Rembert, D.
    Yap, M.
    Dhanda, R.
    Schnadig, I.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S698 - S698
  • [4] Randomized Phase II Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in the Treatment of Metastatic Castration-Resistant Prostate Cancer
    Slovin, Susan F.
    Knudsen, Karen
    Halabi, Susan
    de Leeuw, Renee
    Shafi, Ayesha
    Kang, Praneet
    Wolf, Steven
    Luo, Bin
    Gopalan, Anuradha
    Curley, Tracy
    Fleming, Mark
    Molina, Ana
    Fernandez, Celina
    Kelly, Kevin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (32) : 5015 - +
  • [5] ARN-509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without prior abiraterone acetate (AA) treatment.
    Rathkopf, Dana E.
    Antonarakis, Emmanuel S.
    Shore, Neal D.
    Tutrone, Ronald F.
    Alumkal, Joshi J.
    Ryan, Charles J.
    Saleh, Mansoor N.
    Hauke, Ralph J.
    Bandekar, Rajesh
    Maneval, Edna Chow
    De Boer, Carla
    Todd, Mary Beth
    Yu, Margaret K.
    Scher, Howard I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] PHARMACOECONOMIC EVALUATION OF ABIRATERONE ACETATE VERSUS CABAZITAXEL IN THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN KAZAKHSTAN
    Kostyuk, A.
    Almadiyeva, A.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A412 - A412
  • [7] Abiraterone Acetate In Metastatic Castration-Resistant Prostate Cancer
    Yang, Lily P. H.
    [J]. DRUGS, 2011, 71 (15) : 2067 - 2077
  • [8] Influence of abiraterone acetate on neuroendocrine differentiation in chemotherapy-naive metastatic castration-resistant prostate cancer
    Dong, Baijun
    Fan, Liancheng
    Wang, Yanqing
    Chi, Chenfei
    Ma, Xiaowei
    Wang, Rui
    Cai, Wen
    Shao, Xiaoguang
    Pan, Jiahua
    Zhu, Yinjie
    Xun Shangguan
    Xin, Zhixiang
    Hu, Jianian
    Xie, Shaowei
    Kang, Xiaonan
    Zhou, Lixin
    Xue, Wei
    [J]. PROSTATE, 2017, 77 (13): : 1373 - 1380
  • [9] Cabazitaxel in metastatic castrate resistant prostate cancer (mCRPC) in the era of enzalutamide (ENZA) and abiraterone acetate (AA).
    Body, Amy
    Pranavan, Gane
    Malik, Laeeq
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] An exploratory analysis of efficacy and safety of abiraterone acetate (AA) in black patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (ctx)
    Efstathiou, Eleni
    Deshpande, Hari
    George, Daniel
    Joshua, Anthony M.
    Taplin, Mary-Ellen
    Griffin, Thomas W.
    Londhe, Anil
    Todd, Mary
    Molina, Arturo
    [J]. CANCER RESEARCH, 2014, 74 (19)
12345